Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,557.57
(
0.49%
)
US TECH 100
29,395.60
(
0.75%
)
Dow Jones
50,628.95
(
-0.03%
)
Brent Oil
93.29
(
0.92%
)
Bitcoin
72,801.06
(
-2.78%
)
News Focus
News Focus
Post# of 257649
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123029
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pompart post# 34498

Tuesday, 09/26/2006 8:51:30 AM

Tuesday, September 26, 2006 8:51:30 AM

Post# of 257649
>It will be interesting to see if Quark et al have more luck than Merck & Alnylam did with in vivo delivery.<

I don’t think delivery per se is the limiting issue in RNAi treatment for AMD. Rather, the limiting issue is the need to produce Lucentis-like efficacy without unreasonably frequent intravitreal injections. Regards, Dew

p.s. Just to be clear: MRK/ALNY, Acuity Pharma, and AGN/RNAI are (were) pursuing (pursued) RNA interference of the VEGF gene, while PFE will be pursuing RNA interference of the RTP-801 gene.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today